Humacyte’s (HUMA) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research note released on Wednesday,Benzinga reports. They currently have a $25.00 price target on the stock.

Several other brokerages have also weighed in on HUMA. Benchmark reissued a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Humacyte in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $13.71.

Humacyte Stock Performance

Shares of HUMA stock opened at $2.00 on Wednesday. Humacyte has a 52 week low of $1.96 and a 52 week high of $9.97. The firm’s 50-day simple moving average is $3.71 and its two-hundred day simple moving average is $4.55. The firm has a market cap of $251.72 million, a price-to-earnings ratio of -1.49 and a beta of 1.36.

Institutional Trading of Humacyte

Institutional investors and hedge funds have recently bought and sold shares of the company. Vontobel Holding Ltd. purchased a new stake in shares of Humacyte in the fourth quarter worth $50,000. Petros Family Wealth LLC purchased a new stake in shares of Humacyte in the 4th quarter valued at about $50,000. Syon Capital LLC bought a new stake in shares of Humacyte during the 4th quarter valued at about $54,000. Brookstone Capital Management purchased a new position in shares of Humacyte during the fourth quarter worth about $56,000. Finally, ACT Wealth Management LLC bought a new position in shares of Humacyte in the fourth quarter worth approximately $57,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.